Announcements Trials
Browse Landscape

Phase

Phase 3 5Phase 2 1Phase 1/2 1

Status

Active not recruiting 3Completed 2Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 7

Study Type

Interventional 7

Sponsor

Cancer Type

Gastrointestinal 11Thoracic 8Genitourinary 7Gynecologic 6Dermatologic 5Head & Neck 3Other solid neoplasm 2Breast 2Tumor-Agnostic 1Sarcoma 1NET 1Lymphoid 1Endocrine 1

Conditions

Carcinoma, Renal Cell 3Urinary Bladder Neoplasms 2Urothelial Cancer 1Urologic Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Metastatic Urothelial Cancer 1Carcinoma, Transitional Cell 1

Interventions

pembrolizumab 7Sunitinib 7enfortumab vedotin 6Abiraterone Acetate 6enzalutamide 5Nivolumab 5Gemcitabine 5Cisplatin 5Carboplatin 4avelumab 3Prednisone 3Ipilimumab 3Docetaxel 3Androgen Antagonists 3sacituzumab govitecan 2olaparib 2niraparib 2erdafitinib 2entrectinib 2darolutamide 2cabozantinib 2apalutamide 2Pluvicto 2Mitomycin 2Leuprolide 2Everolimus 2Axitinib 2zimberelimab 1vinflunine 1ulixertinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Has announcements × pembrolizumab × Genitourinary × Clear all
NCT03288545 2026-03-24

EV-103

Astellas Pharma Inc

Phase 1/2 Terminated
348 enrolled 1 FDA
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms, Urologic Neoplasms

NCT03547973 2026-03-16

TROPHY U-01

Gilead Sciences

Phase 2 Recruiting
827 enrolled 1 FDA
Genitourinary

Metastatic Urothelial Cancer

NCT03142334 2026-03-10

KEYNOTE-564

Merck Sharp & Dohme LLC

Phase 3 Completed
994 enrolled 10 charts 1 FDA
Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT02811861 2026-02-23

CLEAR

Eisai Inc.

Phase 3 Active not recruiting
1,069 enrolled 12 charts 1 FDA
Genitourinary

Carcinoma, Renal Cell

NCT02853331 2026-02-02

KEYNOTE-426

Merck Sharp & Dohme LLC

Phase 3 Completed
861 enrolled 24 charts 1 FDA
Genitourinary

Carcinoma, Renal Cell

NCT03924895 2025-08-28

KEYNOTE-905

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
595 enrolled 1 FDA
Genitourinary

Urinary Bladder Neoplasms

NCT04223856 2025-06-13

EV-302

Astellas Pharma Inc

Phase 3 Active not recruiting
886 enrolled 12 charts 1 FDA
Genitourinary

Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡